TY  - RPRT
TI  - Optimal Individualized Combination Immunotherapy/Oncolytic Virotherapy Determined Through In Silico Clinical Trials Improves Late Stage Melanoma Patient Outcomes
AU  - Cassidy, T.
AU  - Craig, M.
PY  - 2019
DO  - 10.1101/585711
UR  - https://www.biorxiv.org/content/10.1101/585711v1
ID  - 10.1101/585711
ER  -